ClinicalTrials.gg
CompletedNCT04270942Updated Feb 12, 2025Results posted

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

A Phase 2 interventional study of teplizumab 1 mg/mL in Diabetes Mellitus, Type 1, sponsored by Provention Bio, a Sanofi Company. Completed at 8 sites in United States. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Provention Bio, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.

Enrollment
10th of 11
6 · median 60
Started
2020
the only one that year
Phase 2
4 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Provention Bio, a Sanofi Company

Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 2, and was the 7th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teplizumab

teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing teplizumab in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the conclusion of that trial, were eligible to enroll and receive teplizumab treatment within one year of diagnosis of clinical type 1 diabetes.

Read the detailed description

The study was a single-arm, multicenter, open-label clinical trial. All participants received a 12-day course of teplizumab given through daily IV infusion and were followed for 78 weeks.

The purpose of this study was to evaluate the safety and tolerability of teplizumab treatment, administered intravenously (IV) to participants in the NIH-sponsored trial who have developed type 1 diabetes and were able to start teplizumab treatment within 1 year of diagnosis of type 1 diabetes. Whether teplizumab treatment reduced the loss of insulin-producing pancreatic beta cells were evaluated.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Recent-onset type 1 diabetes
  • Teplizumab
  • T1D
  • Stage 3
  • Type 1 diabetes
  • New onset type 1 diabetes
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previous participant in the TN-10 study
  2. Participant had received a diagnosis of type 1 diabetes after the conclusion of the TN-10 study, according to the criteria from the American Diabetes Association (ADA).
  3. Participant was able to initiate teplizumab treatment required in this study within 1 year of type 1 diabetes diagnosis.
  4. Participant was willing to forego other forms of experimental treatment during the entire study.
  5. Participant and/or guardian had given and assent as applicable.

Exclusion criteria

Exclusion Criteria:

  1. Had an active infection and/or fever.
  2. Had a history of or serologic evidence at screening of current or past infection with (HIV), virus (HBV), or virus (HCV).
  3. An individual who had a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Teplizumab treated

    Administration of teplizumab by intravenous infusion for 12 consecutive days

    Drug: teplizumab 1 mg/mL

Interventions

  • Drugteplizumab 1 mg/mL

    Drug page: Teplizumab

    Solution for infusion administered as IV infusion (anti-CD3 humanized monoclonal antibody). Cumulative dose: 9 mg/m2. Day 1: 106 μg/m2, Day 2: 425 μg/m2, Days 3-12: 850 μg/m2 daily

    Also known as: PRV-031, Tzield

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Events of Special Interest (TEAESIs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was any untoward medical occurrence in a participant or clinical study participant,temporally associated with use of study dose,whether or not considered related to study dose.AESI was any AE that met any of following:All \>=Grade 3 infections (including all opportunistic infections);acute mononucleosis-like illness;lymphomas or other malignancies;severe hypoglycemic episode;\>=Grade 3 liver function abnormalities, thrombocytopenia, neutropenia or rash;\>= Grade 4 allergic/hypersensitivity reaction (anaphylaxis) or cytokine-release syndrome; lymphocyte count \<500/cubic millimeter for 7 days or longer. An SAE was as any untoward medical occurrence that,at any dose:resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization,resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or any other medically important event.A TEAE was any AE which started during or after the first dose of teplizumab.

    Time frame: From the first dose of study drug administration (Day 1) up to approximately 78 weeks

Secondary outcomes

  1. Serum Concentration Immediately Prior to Administration of the Next Dose (Ctrough) of Teplizumab at Day 364

    Blood samples were collected for evaluation of pharmacokinetic (PK) data.

    Time frame: Pre-dose on Day 364

  2. Number of Participants With Anti-drug Antibodies (ADA) Against Teplizumab

    Blood samples were collected for the evaluation of ADA against teplizumab.

    Time frame: Up to Day 364

  3. Area Under the Time-Versus-Concentration Curve (AUC) of C-peptide After a 4-hour (4h) Mixed Meal Tolerance Test (MMTT) at Week 78

    The AUC of C-peptide was measured after a 4-hour MMTT as a measure of assessing endogenous insulin production and beta cell function. The AUC was computed using the trapezoidal rule and standardized by the duration of the MMTT test for the analysis.

    Time frame: Week 78

  4. Glycated Hemoglobin (HbA1c) Levels at Week 78

    Blood samples were collected for evaluation of HbA1c.

    Time frame: Week 78

  5. Average Daily Use of Exogenous Insulin at Week 78

    The average daily insulin use was calculated based on participants who had at least 3 days of insulin use recorded in the diary for the Week 78 visit.

    Time frame: Week 78

  6. Number of Participants With Severe Hypoglycemic Episodes

    The severity of a hypoglycemia event was identified by the Investigator and classified according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 as follows: * Grade 3 hypoglycemia: 30-39 milligram/deciliter (mg/dL) (1.7-2.1 millimole \[mmol\]/L). This is considered severe or medically significant but not immediately life-threatening. Hospitalization or prolongation of hospitalization is likely indicated. It is considered disabling and limits self-care. * Grade 4 hypoglycemia: \<=29 mg/dL (1.6 mmol/L). This is considered life threatening (seizures) with urgent intervention indicated. * Grade 5 hypoglycemia: Hypoglycemia resulting in death. Hypoglycemia \>=Grade 3 was considered as severe hypoglycemia.

    Time frame: From the first dose of study drug administration (Day 1) up to approximately 78 weeks

  7. Number of Participants With Change in Cluster of Differentiation (CD)8+ TIGIT+ KLRG1+ T Cells

    CD8+ TIGIT+ KLRG1+ T cells were measured using flow cytometry.

    Time frame: From the first dose of study drug administration (Day 1) up to approximately 78 weeks

07

Results

Posted Feb 12, 2025

Participant flow

The study was conducted in the United States from 26-Feb-2020 to 22-Jan-2024.

Participant flow — Overall Study
MilestoneTeplizumab
Started6
Completed5
Not completed1
Withdrew: Death1

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Events of Special Interest (TEAESIs) and Treatment-emergent Serious Adverse Events (TESAEs)

An AE was any untoward medical occurrence in a participant or clinical study participant,temporally associated with use of study dose,whether or not considered related to study dose.AESI was any AE that met any of following:All \>=Grade 3 infections (including all opportunistic infections);acute mononucleosis-like illness;lymphomas or other malignancies;severe hypoglycemic episode;\>=Grade 3 liver function abnormalities, thrombocytopenia, neutropenia or rash;\>= Grade 4 allergic/hypersensitivity reaction (anaphylaxis) or cytokine-release syndrome; lymphocyte count \<500/cubic millimeter for 7 days or longer. An SAE was as any untoward medical occurrence that,at any dose:resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization,resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or any other medically important event.A TEAE was any AE which started during or after the first dose of teplizumab.

Time frame:
From the first dose of study drug administration (Day 1) up to approximately 78 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Events of Special Interest (TEAESIs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsTeplizumab
Any TEAE6
Any TEAESI0
Any TESAE1
SecondarySerum Concentration Immediately Prior to Administration of the Next Dose (Ctrough) of Teplizumab at Day 364

Blood samples were collected for evaluation of pharmacokinetic (PK) data.

Time frame:
Pre-dose on Day 364
Reported as:
Mean · nanogram/milliliter (ng/mL)
Serum Concentration Immediately Prior to Administration of the Next Dose (Ctrough) of Teplizumab at Day 364
nanogram/milliliter (ng/mL)Teplizumab
Serum Concentration Immediately Prior to Administration of the Next Dose (Ctrough) of Teplizumab at Day 364NA ± NA
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) Against Teplizumab

Blood samples were collected for the evaluation of ADA against teplizumab.

Time frame:
Up to Day 364
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA) Against Teplizumab
ParticipantsTeplizumab
Number of Participants With Anti-drug Antibodies (ADA) Against Teplizumab6
SecondaryArea Under the Time-Versus-Concentration Curve (AUC) of C-peptide After a 4-hour (4h) Mixed Meal Tolerance Test (MMTT) at Week 78

The AUC of C-peptide was measured after a 4-hour MMTT as a measure of assessing endogenous insulin production and beta cell function. The AUC was computed using the trapezoidal rule and standardized by the duration of the MMTT test for the analysis.

Time frame:
Week 78
Reported as:
Mean · ln(AUC+1) (picomole/mL)
Area Under the Time-Versus-Concentration Curve (AUC) of C-peptide After a 4-hour (4h) Mixed Meal Tolerance Test (MMTT) at Week 78
ln(AUC+1) (picomole/mL)Teplizumab
Area Under the Time-Versus-Concentration Curve (AUC) of C-peptide After a 4-hour (4h) Mixed Meal Tolerance Test (MMTT) at Week 780.549 ± 0.4276
SecondaryGlycated Hemoglobin (HbA1c) Levels at Week 78

Blood samples were collected for evaluation of HbA1c.

Time frame:
Week 78
Reported as:
Mean · percentage of HbA1c
Glycated Hemoglobin (HbA1c) Levels at Week 78
percentage of HbA1cTeplizumab
Glycated Hemoglobin (HbA1c) Levels at Week 788.50 ± 3.785
SecondaryAverage Daily Use of Exogenous Insulin at Week 78

The average daily insulin use was calculated based on participants who had at least 3 days of insulin use recorded in the diary for the Week 78 visit.

Time frame:
Week 78
Reported as:
Mean · unit/kilogram/day
Average Daily Use of Exogenous Insulin at Week 78
unit/kilogram/dayTeplizumab
Average Daily Use of Exogenous Insulin at Week 780.54 ± 0.357
SecondaryNumber of Participants With Severe Hypoglycemic Episodes

The severity of a hypoglycemia event was identified by the Investigator and classified according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 as follows: * Grade 3 hypoglycemia: 30-39 milligram/deciliter (mg/dL) (1.7-2.1 millimole \[mmol\]/L). This is considered severe or medically significant but not immediately life-threatening. Hospitalization or prolongation of hospitalization is likely indicated. It is considered disabling and limits self-care. * Grade 4 hypoglycemia: \<=29 mg/dL (1.6 mmol/L). This is considered life threatening (seizures) with urgent intervention indicated. * Grade 5 hypoglycemia: Hypoglycemia resulting in death. Hypoglycemia \>=Grade 3 was considered as severe hypoglycemia.

Time frame:
From the first dose of study drug administration (Day 1) up to approximately 78 weeks
Reported as:
Count of participants · Participants
Number of Participants With Severe Hypoglycemic Episodes
ParticipantsTeplizumab
Number of Participants With Severe Hypoglycemic Episodes0
SecondaryNumber of Participants With Change in Cluster of Differentiation (CD)8+ TIGIT+ KLRG1+ T Cells

CD8+ TIGIT+ KLRG1+ T cells were measured using flow cytometry.

Time frame:
From the first dose of study drug administration (Day 1) up to approximately 78 weeks
Reported as:
Count of participants · Participants
Number of Participants With Change in Cluster of Differentiation (CD)8+ TIGIT+ KLRG1+ T Cells
ParticipantsTeplizumab
Number of Participants With Change in Cluster of Differentiation (CD)8+ TIGIT+ KLRG1+ T Cells4

Adverse events

Collected over From the first dose of study drug administration (Day 1) up to approximately 78 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teplizumab1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventTeplizumab
Completed SuicidePsychiatric disorders1/6
Most frequent other events
Showing 10 of 33
Most frequent other events
EventTeplizumab
HeadacheNervous system disorders4/6
LymphopeniaBlood and lymphatic system disorders3/6
NauseaGastrointestinal disorders3/6
LeukopeniaBlood and lymphatic system disorders2/6
VomitingGastrointestinal disorders2/6
PyrexiaGeneral disorders2/6
RashSkin and subcutaneous tissue disorders2/6
NeutropeniaBlood and lymphatic system disorders1/6
BradycardiaCardiac disorders1/6
ChillsGeneral disorders1/6

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of teplizumab.

Age, Continuous
Age, Continuous(years)Teplizumab
Mean21.3 ± 11.59
Sex: Female, Male
Sex: Female, Male(Participants)Teplizumab
Female3
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Teplizumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported0
08

Study locations

8 sites
  • Barbara Davis Center for Diabetes Site Number : 04
    Aurora, Colorado 80045, United States
  • Clinical Site
    Aurora, Colorado 80045, United States
  • Yale University School of Medicine Site Number : 01
    New Haven, Connecticut 06511, United States
  • Clinical Site
    New Haven, Connecticut 06519, United States
  • Clinical Site
    Gainesville, Florida 32610, United States
  • University of Florida Site Number : 02
    Gainesville, Florida 32610, United States
  • Clinical Site
    Nashville, Tennessee 37232, United States
  • Vanderbilt Univerity Medical Center Site Number : 03
    Nashville, Tennessee 37232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Jan 2024, 46 months.

Results were first posted in Feb 2025, 1 year after primary completion.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 46 months is above that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2020
First posted
Feb 17, 2020
StartActual
Feb 26, 2020
Primary completionActual
Jan 22, 2024
CompletionActual
Jan 22, 2024
Results first posted
Feb 12, 2025
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04270942
Responsible party
Sponsor
First posted
Feb 17, 2020
Start date
Feb 26, 2020
Primary completion
Jan 22, 2024
Completion
Jan 22, 2024
Results posted
Feb 12, 2025
Last update
Feb 12, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teplizumab

Start the discussion